Numis Securities Ltd restated their buy rating on shares of Circassia Pharmaceuticals PLC (LON:CIR) in a report issued on Wednesday morning. Numis Securities Ltd currently has a GBX 180 ($2.42) target price on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Peel Hunt restated a hold rating and issued a GBX 130 ($1.75) price target on shares of Circassia Pharmaceuticals PLC in a research note on Wednesday. J P Morgan Chase & Co restated a neutral rating on shares of Circassia Pharmaceuticals PLC in a research note on Friday, September 8th.

Shares of Circassia Pharmaceuticals PLC (LON:CIR) traded down 0.90% during midday trading on Wednesday, reaching GBX 82.25. The company’s stock had a trading volume of 24,931 shares. The company’s market capitalization is GBX 234.10 million. The stock has a 50 day moving average of GBX 87.40 and a 200-day moving average of GBX 92.23. Circassia Pharmaceuticals PLC has a 1-year low of GBX 76.75 and a 1-year high of GBX 114.00.

TRADEMARK VIOLATION NOTICE: “Circassia Pharmaceuticals PLC (CIR) Receives “Buy” Rating from Numis Securities Ltd” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/28/circassia-pharmaceuticals-plc-cir-receives-buy-rating-from-numis-securities-ltd.html.

Circassia Pharmaceuticals PLC Company Profile

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

Receive News & Stock Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.